{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-001506","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.825653+00:00","generated_at":"2026-06-22T09:29:57.734857+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Edgewise Q3 net loss $17.5M ($0.34/shr); cash $365M; EDG-5506 shows biomarker reductions","bullets":["Cash, equivalents and marketable securities $365M as of Sept 30, 2022; underwritten offering raised $129M net.","Net loss $17.5M ($0.34 per share) vs $16.1M ($0.32) prior quarter; R&D spend $13.9M.","Positive 6-month ARCH interim data: CK reduced 39%, fast skeletal troponin I reduced 75% in BMD adults.","CANYON Phase 2 trial in BMD (n≈66) and LYNX Phase 2 trial in DMD (n≈27) both advancing; no approved treatments.","EDG-002 preclinical program targets hypertrophic cardiomyopathy; IND-enabling studies planned for 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-001506","json":"https://secwatch.observer/filing/0001157523-22-001506.json","markdown":"https://secwatch.observer/filing/0001157523-22-001506.md","text":"https://secwatch.observer/filing/0001157523-22-001506.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000115752322001506/0001157523-22-001506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000115752322001506/a52959492.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:29:57.734857+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b8385d7bf79ebff9d28267cf19ccd844825c3cc","claim":"Edgewise Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 3, 2022, Edgewise Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1710072/000115752322001506/0001157523-22-001506-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}